S&T Bank’s Vaxcyte PCVX Stock Holding History

S&T Bank’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-43	Closed	-$1.62K	–	482
2025 Q1	$1.62K	Buy	+43	New	+$3.44K	﹤0.01%	324

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

S&T Bank's PCVX Position: Q2 2025 in Review

S&T Bank sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 43 shares — an estimated $1.62K sold.

S&T Bank first reported a position in PCVX in Q1 2025 and held it in 1 quarter. The position peaked at $1.62K in Q1 2025. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

S&T Bank reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
S&T Bank sold 43 Vaxcyte shares in Q2 2025, an estimated $1.62K.
S&T Bank first reported a position in Vaxcyte in Q1 2025 and held it in 1 quarter.
S&T Bank's Vaxcyte position peaked at $1.62K in Q1 2025.
294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on S&T Bank's 13F filing for Q2 2025, filed 6 Aug 2025.